{"url_path":"/sec/slncf/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-229089-index.html","accession_number":"0001193125-26-229089","cik":"0001479615","ticker":"SLN","issuer_name":"Silence Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-229089-index.html","primary_entity_key":"0001479615","primary_entity_name":"Silence Therapeutics plc"},"word_count":453,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d) Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\n1.1\n\n[Open Market Sale AgreementSM by and between the Registrant and Jefferies LLC, dated May 18, 2026](https://www.sec.gov/Archives/edgar/data/1479615/000119312526228915/d120718dex12.htm )(incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 (File No. 333-295992), filed with the Securities and Exchange Commission on May 18, 2026)\n\n5.1\n\n \n\n[Opinion of Cooley (UK) LLP](https://www.sec.gov/Archives/edgar/data/1479615/000119312526228915/d120718dex51.htm) (incorporated by reference to Exhibit 5.1 to the Company’s Registration Statement on Form S-3 (File No. 333-295992), filed with the Securities and Exchange Commission on May 18, 2026)\n\n23.1\n\n \n\n[Consent of Cooley LLP](https://www.sec.gov/Archives/edgar/data/1479615/000119312526228915/d120718dex51.htm) (included in Exhibit 5.1)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nCautionary Note Regarding Forward-Looking Statements\n\n \n\nThis Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the Company’s expectations as to PFIC classification for the taxable year ended December 31, 2025. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the likelihood of cash exercise during the extended term and potential proceeds to be received by the Company. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequent filings with the SEC. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nSILENCE THERAPEUTICS PLC\n\nDate: May 18, 2026\n\nBy:\n\n /s/ Iain Ross\n\nName: Iain Ross\n\nTitle: Interim Principal Executive Officer and Chairman of the Board of Directors\n\n(Principal Executive Officer)"}